PRIMO 2024 | Personalizing therapy for high-risk HR+ breast cancer: insights from monarchE and NATALEE trials

William J. Gradishar, MD, FASCO FACP, Feinberg School of Medicine, Chicago, IL, discusses the Phase III monarchE (NCT03155997) and NATALEE (NCT03701334) trials, which aimed to personalize therapy for patients with breast cancer based on individual risk factors. These trials utilized clinical features such as nodal status, tumor size, and proliferation markers like Ki-67 to categorize patients as high risk for recurrence. Prof. Gradishar highlights the importance of using tools like the breast cancer index to determine the need for extended therapy with aromatase inhibitors in certain patients. By identifying subsets of patients at higher risk, clinicians can tailor treatment regimens accordingly, ensuring that individuals receive the most appropriate therapies for their specific circumstances. This interview took place at the 2024 PRIMO meeting in Honolulu, Hawaii.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.